http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013203816-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00755170c71be0ffa84977249cd628b5 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095 |
| filingDate | 2013-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f97f96146f55df40f2ee2a4ec7ec4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a3efc458145fc72321a45f8cc93c07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ba556323e9d07444b60a8fcbaa8078 |
| publicationDate | 2013-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013203816-A1 |
| titleOfInvention | Immunising against meningococcal serogroup Y using proteins |
| abstract | The established dogma for meningococcus is thus that immunisation against serogroups A, C, W135 and Y shall be based on the four different capsular saccharides, and that immunisation against serogroup B shall not be based on the capsular saccharide. In contrast, the invention uses polypeptide antigens and/or OMVs to immunise against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W 135 and Y. |
| priorityDate | 2004-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 249.